Combination of copeptin, placental growth factor and total annexin V microparticles for prediction of preeclampsia at 10–14 weeks of gestation

Abstract

IntroductionPreeclampsia (PE) remains to be an enigmatic puzzle for clinicians and researchers perplexing them for decades. As delivery remains only choice of treatment, early prediction of PE will offer timely therapeutic invention and hence extensive research efforts have been put in identification of biomarkers which will facilitate early prediction of PE. MethodsSerum levels of CPP, PlGF and plasma total annexin V MPs were assessed in women who subsequently developed PE (n = 33), IUGR (n = 81) and normal pregnancy outcome (n = 112) at 10–14 weeks of gestation. Comparison of biomarker levels between patients and control group was done using Mann Whitney test. Receiver operating curve (ROC) analysis and binary logistic regression analysis were used to evaluate predictive utility of combination of CPP, PlGF and total annexin V MPs for prediction of PE. ResultsWomen who subsequently developed PE showed significantly elevated levels of total annexin V MPs [2766.04 (2086.88–3794) versus 1090.74 (631.91–2197.16)] and CPP [440.98 (365.12–488.92) versus 217.8 (171.13–308.98)] compared to controls. Serum PlGF levels were significantly reduced in women with PE 17.68 (12.66–22.32) compared to controls 105.22 (35.02–255.1). Using logistic regression analysis, the combination of CPP, PlGF and total annexin V MPs gave high predictive value with AUC of 0.970, 93.1% sensitivity, 90.7% specificity, 77.50% Positive predictive value, 98.10% Negative predictive value, 11.69 Positive likelihood ratio and 0.07 Negative likelihood ratio for PE prediction at 10–14 weeks. ConclusionThe combination of serum markers and plasma microparticles can be used for 10–14 weeks prediction and discrimination of PE from other pregnancy complications.